Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Depreciation & Amortization (CF) (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 4.13% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.3 million through Dec 2025, up 1.68% year-over-year, with the annual reading at $22.3 million for FY2025, 1.68% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $5.7 million at Beam Therapeutics, up from $5.6 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $5.7 million in Q4 2025, with the low at $1.4 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $4.3 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) surged 136.91% in 2022, then dropped 0.68% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $2.6 million in 2021, then soared by 49.73% to $3.9 million in 2022, then skyrocketed by 35.95% to $5.4 million in 2023, then grew by 1.51% to $5.4 million in 2024, then rose by 4.13% to $5.7 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $5.7 million, $5.6 million, and $5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.